Eric Young has extensive work experience in the field of business development and finance. Eric is currently serving as the Chief Business Officer at BiomEdit since March 2023. Prior to their current role, Eric held the position of Head of Business Development at Elanco from December 2020 to March 2023, where they led a team focused on strategic value creation initiatives and projects through innovative financial transactions and deal structures. Before joining Elanco, Eric had a long tenure at Eli Lilly and Company, where they served as the Head of Investment Management and Global Treasury in the Corporate Finance and Business Development division from July 2001 to December 2020. Additionally, Eric has also held the role of Member Investment Committee of the Board at the Indiana Biosciences Research Institute since September 2016. Throughout their career, Eric has been involved in various strategic transactions such as non-traditional M&A, licensing, JV partnerships, and divestitures, creating both near-term and future opportunities for the organizations they have worked with.
Eric Young has a Bachelor of Science (B.S.) degree in Finance from Indiana University - Kelley School of Business. Eric also holds a Master of Business Administration (MBA) degree in Finance from the same institution.
March, 2023 - present